```
(FILE 'MEDLINE, AGRICOLA, CANCERLIT, SCISEARCH, CAPLUS, MEDICONF' ENTERED
    AT 14:27:04 ON 11 FEB 2004)
                DEL HIS
         390576 S FIBROBLAST?
L1
L2
          21866 S L1 AND (EXTRACELLULAR MATRIX)
          12393 S L2 AND (COLLAGEN OR DECORIN OR FIBRONECTIN OR TENASCIN OR GL
L3
L4
           2594 S L3 AND SKIN
           146 S L4 AND (TRANSPLANT? OR GRAFT OR BIOENGINE?)
L5
             95 DUP REM L5 (51 DUPLICATES REMOVED)
1.6
1.7
             95 FOCUS L6 1-
             55 S L7 AND PY<=1999
^{\rm L8}
             55 SORT L8 PY
L_9
                E MURPHY MICHAEL?/AU
                E MURPHY MICHAEL/AU
L10
            103 S E28
L11
              8 S L10 AND L1
              6 DUP REM L11 (2 DUPLICATES REMOVED)
L12
L13
              6 SORT L12 PY
               E RONFARD VINCENT?/AU
L14
              9 S E2
             13 S E1
L15
              0 S L14 AND L15
L16
L17
             22 S L14 OR L15
L18
             15 DUP REM L17 (7 DUPLICATES REMOVED)
              5 S L18 AND L1
T.19
=> d an ti so au ab pi 119 1 3-5
L19 ANSWER 1 OF 5
                       MEDLINE on STN
     2003072369
                   MEDLINE
AN
     Long-term remodeling of a bilayered living human skin equivalent
     (Apligraf) grafted onto nude mice: immunolocalization of human cells and
     characterization of extracellular matrix.
     WOUND REPAIR AND REGENERATION, (2003 Jan-Feb) 11 (1) 35-45.
     Journal code: 9310939. ISSN: 1067-1927.
     Guerret Sylviane; Govignon Emmanuel; Hartmann Daniel J; Ronfard
AU
AB
     Type I collagen is a clinically approved biomaterial largely used in
     tissue engineering. It acts as a regenerative template in which the
     implanted collagen is progressively degraded and replaced by new
     cell-synthesized tissue. Apligraf, a bioengineered living skin, is
     composed of a bovine collagen lattice containing living human
     fibroblasts overlaid with a fully differentiated epithelium made
     of human keratinocytes. To investigate its progressive remodeling,
     athymic mice were grafted and the cellular and the extracellular matrix
     components were studied from 0 to 365 days after grafting. Biopsies were
     analyzed using immunohistochemistry with species-specific antibodies and
     electron microscopy techniques. We observed that this bioengineered
     tissue provided living and bioactive cells to the wound site up to 1 year
     after grafting. The graft was rapidly incorporated within the host tissue
     and the bovine collagen present in the graft was progressively replaced by
     human and mouse collagens. A normal healing process was observed, i.e.,
     type III collagen appeared transiently with type I collagen, the major
     collagen isoform present at later stages. New molecules, such as elastin,
     were produced by the living human cells contained within the graft. This
     animal model combined with species-specific immunohistochemistry tools is
     thus very useful for studying long-term tissue remodeling of bioengineered
     living tissues.
L19 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     2002:171741 CAPLUS
DN
     136:205388
     Methods and compositions for tissue regeneration
TI
     PCT Int. Appl., 35 pp.
SO
     CODEN: PIXXD2
IN
     Baetge, Edward E.; Hunziker, Thomas; Ronfard, Vincent
     The present invention provides the use and composition of matter of angiogenic
AB
     or other growth factors expressed by combining various types and stages of
     differentiation of allogeneic human cell strains or lines in
```

unencapsulated pastes (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) to be temporarily applied to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

```
PATENT NO.
                         KIND DATE
                                                APPLICATION NO. DATE
                                                 WO 2001-US27104 20010831
     WO 2002017980
                               20020307
PΙ
                         A2
                         A3
                                20020530
     WO 2002017980
     WO 2002017980
                         C2
                                20030320
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
              KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
               IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
               GQ, GW, ML, MR, NE, SN, TD, TG
                                                 US 2001-943114
                                                                    20010830
     US 2002048563
                         A1
                                20020425
     US 6673603
                          B2
                                20040106
                                                 AU 2001-86952
                                                                    20010831
     AU 2001086952
                          Α5
                                20020313
                                                 EP 2001-966441
                                                                    20010831
     EP 1326654
                         A2
                                20030716
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
L19 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
```

- 2001:152814 CAPLUS AN
- Skin care compositions and treatments TI
- SO PCT Int. Appl., 69 pp. CODEN: PIXXD2
- Ronfard, Vincent; Tuck, Alan W.; Wilkins, Leon M. IN
- The invention is directed to compns. containing growth agents synthesized from cultured cells from skin. Skin cells such as keratinocytes and dermal fibroblasts are cultured in vitro in cell medium and in the course of culture the cultured cells synthesize and secrete agents into the cell medium. The medium containing agents are collected and incorporated into pharmaceutical or cosmetic prepns. to treat an individual. The preparation is applied and has a rejuvenating effect on the cells and tissue. PATENT NO. KIND DATE APPLICATION NO. DATE

```
WO 2000-US23178 20000823
                                20010301
WO 2001014527
                        A1
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
           HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
           YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
           DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

- ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN L19
- AN 2000:351643 CAPLUS
- DN 132:331698
- Bioengineered tissue constructs and methods for producing and using them TI
- PCT Int. Appl., 68 pp. SO CODEN: PIXXD2
- IN Murphy, Michael P.; Ronfard, Vincent
- Cultured tissue constructs comprising cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphol. features and functions similar to tissues and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention are prepared in defined media, i.e., without the addition of chemical

	und	defin	ed c	ompoi	hent	s.													
	PAT	PATENT NO.				KIND DATE				APPLICATION NO. DATE									
													- <b>-</b>						
ΡI	WO 2000029553			A1 20000525			0525		WO 1999-US27505 19991119										
		W: .	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
			DK,	EE,	ES,	FI,	GB,	GE,	GH,	HU,	IL,	IS,	JP,	KE,	KG,	ΚP,	KR,	ΚZ,	
			LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NΖ,	PL,	
			PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	UA,	UG,	US,	
			UΖ,	VN,	YU,	ZW,	AM,	ΑZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	MT				
		RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,	
			DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	ΙT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	
			CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG					
	EP	2 1131410			A1 20010912					EP 1999-962807 19991119									
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			ΙE,	$_{ m FI}$															
	BR	R 9915476			A 2002		0102		BR 1999-15476				:	19991119					
	JP	2002530069			T2 2002091			0917		JP 2000-582537					19991119				
	US	2002	002172705		A.	A1 2002		1121		U	US 2000-523809				20000313				

- L9 ANSWER 44 OF 55 MEDLINE on STN
- AN 1998207044 MEDLINE
- TI Analysis of matrix protein components of the dermis-like structure formed in a long-term culture of human **fibroblasts**: type VI **collagen** is a major component.
- SO JOURNAL OF BIOCHEMISTRY, (1998 Apr) 123 (4) 587-95. Journal code: 0376600. ISSN: 0021-924X.
- AU Hazeki N; Yamato M; Imamura Y; Sasaki T; Nakazato K; Yamamoto K; Konomi H; Hayashi T
- Formation of a dermis-like structure by a long-term culture of fibroblasts in the presence of ascorbic acid is a potential model for tissue organization or wound healing, and has its practical use as a skin graft. In the present study, solubilization of the dermis-like structure without pepsin treatment was attempted for analysis of pepsin-labile matrix components that might be involved in the formation of the dermis-like structure, as well as quantification of mutated type I collagen that could be susceptible to pepsin. The whole dermis-like structure was dissolved in a Tris buffer containing SDS and urea at 80 degreesC. Analysis of the extract by SDS-PAGE revealed several protein bands that were not found in the pepsin-treated extract. Among them, the polypeptide band migrating at 140k under reducing condition showed a similar intensity of protein staining to the alpha2(I) chain band. The N-terminal amino acid sequences of cyanogen bromide peptides derived from the 140k polypeptide band as well as the amino acid composition of the band suggested that the band essentially consisted of alphal(VI) and alpha2(VI) chains. The results demonstrated that the type VI collagen was a major component, being a comparable in amount to type I collagen, in the dermis-like structure.

STN: SEARCH HISTORY

- L9 ANSWER 43 OF 55 MEDLINE on STN
- AN 1998281608 MEDLINE
- TI .Organized skin structure is regenerated in vivo from collagen-GAG matrices seeded with autologous keratinocytes.
- SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1998 Jun) 110 (6) 908-16. Journal code: 0426720. ISSN: 0022-202X.
- AU Compton C C; Butler C E; Yannas I V; Warland G; Orgill D P
  - A well-characterized collagen-glycosaminoglycan matrix (CGM) that has been shown to function as a dermal analog was seeded with freshly disaggregated autologous keratinocytes and applied to full-thickness wounds in a porcine model. CGM were impregnated with 50,000 keratinocytes per cm2, a seeding density that produces a confluent epidermis within 19 d post-grafting and affords a 60-fold surface expansion of the donor epidermis. In this study, the temporal sequence of events in epidermal and neodermal formation was analyzed histopathologically and immunohistochemically from 4 to 35  $\ensuremath{\text{d}}$ post-grafting. The epidermis was observed to form from clonal growth of individual keratinocytes into epithelial cords and islands that gradually enlarged, coalesced, differentiated to form large horn cysts, and finally reorganized at the graft surface to form a fully differentiated, normally oriented epidermis with rete ridges. Simultaneously, a neodermis formed from migration of endothelial cells, fibroblasts, and macrophages into the CGM from the underlying wound bed, resulting in formation of blood vessels, the production of abundant extracellular matrix, and the degradation of the CGM fibers, respectively. Gradually, the stromal cellularity of the CGM decreased and collagen deposition and remodeling increased to form a neodermal connective tissue matrix beneath the newly formed epidermis. Complete dissolution of the CGM occurred, partly as a result of degradation by an ongoing foreign-body giant cell reaction that peaked at 8-12 d post-grafting, but neither acute inflammation nor evidence of immune stimulation were observed. Within 1 mo, many structural components of normal skin were reconstituted.

STN: SEARCH HISTORY

- L9 ANSWER 42 OF 55 MEDLINE on STN
- AN 1998437322 MEDLINE
- TI In vitro reconstruction of a human capillary-like network in a tissue-engineered **skin** equivalent.
- SO FASEB JOURNAL, (1998 Oct) 12 (13) 1331-40. Journal code: 8804484. ISSN: 0892-6638.
- AU Black A F; Berthod F; L'heureux N; Germain L; Auger F A
- For patients with extensive burns, wound coverage with an autologous in ABvitro reconstructed skin made of both dermis and epidermis should be the best alternative to split-thickness graft. Unfortunately, various obstacles have delayed the widespread use of composite skin substitutes. Insufficient vascularization has been proposed as the most likely reason for their unreliable survival. Our purpose was to develop a vascular-like network inside tissue-engineered skin in order to improve graft vascularization. To reach this aim, we fabricated a collagen biopolymer in which three human cell types keratinocytes, dermal fibroblasts, and umbilical vein endothelial cells were cocultured. We demonstrated that the endothelialized skin equivalent (ESE) promoted spontaneous formation of capillary-like structures in a highly differentiated extracellular matrix. Immunohistochemical analysis and transmission electron microscopy of the ESE showed characteristics associated with the microvasculature in vivo (von Willebrand factor, Weibel-Palade bodies, basement membrane material, and intercellular junctions). We have developed the first endothelialized human tissue-engineered skin in which a network of capillary-like tubes is formed. The transplantation of this ESE on human should accelerate graft revascularization by inosculation of its preexisting capillary-like network with the patient's own blood vessels, as it is observed with autografts. In addition, the ESE turns out to be a promising in vitro angiogenesis model.

STN: SEARCH HISTORY